@article{fdi:010062019,
  title = {{E}valuation of four {T}enofovir-containing regimens as first-line treatments in {C}ameroon and {S}enegal : the {ANRS} 12115 {DAYANA} {T}rial},
  author = {{L}andman, {R}. and {K}oulla-{S}hiro, {S}. and {S}ow, {P}. {S}. and {N}golle, {M}. and {D}iallo, {M}. {B}. and {G}ueye, {N}. {F}. {N}. and {L}e {M}oing, {V}. and {E}ymard-{D}uvernay, {S}abrina and {B}enalycherif, {A}. and {C}harpentier, {C}. and {P}eytavin, {G}. and {D}elaporte, {E}ric and {G}irard, {P}. {M}.},
  editor = {},
  language = {{ENG}},
  abstract = {{B}ackground: {T}he aim of the present study was to determine appropriate tenofovir-based regimens meriting evaluation in large-scale randomized trials among sub-{S}aharan {A}frican patients. {M}ethods: {T}his was a randomized open-label 96-week prospective pilot study evaluating four first-line regimens: tenofovir/emtricitabine/nevirapine (group 1),tenofovir/lopinavir/ritonavir(group 2), tenofovir/emtricitabine/zidovudine (group 3) and tenofovir/emtricitabine/ efavirenz (group 4) in antiretroviral-naive, {HIV}-1-infected patients in {S}enegal and {C}ameroon. {T}he primary end point was defined as an {HIV}-1 {RNA} viral load < 50 copies/ml (study detection limit) at week 16 in >= 50% of patients using intention-to-treat analysis. {R}esults: {A}t baseline, 119 patients included were 34% male, had a median plasma viral load of 5.4 log 10 copies/ml and median {CD}4(+) {T}-cell count of 200 cells/mm(3) range 53-358). {T}he primary end point was achieved for groups 1, 3 and 4 (58% [n=31], 62% [n=29] and 53% [n=30], respectively), but not for group 2 (38% [n=29]). {A}t week 96, undetectable {HIV}-1 {RNA} had been achieved in 74% of patients in group 1, 38% in group 2, 72% in group 3 and 73% in group 4. {P}atients with detectable {HIV}-1 {RNA} at week 16 were more likely to have baseline {HIV}-1 {RNA} >= 100,000 copies/ml (adjusted {OR} 5.56, 95% {CI} 1.72, 16.67). {HIV} mutations associated with protease inhibitor resistance emerged in three patients, all of whom were in group 2. {A}naemia occurred in two group 3 patients and was the only serious treatment-related adverse event. {C}onclusions: {T}hree efficient and safe tenofovir-based triple regimens were identified; the two-drug regimen (tenofovir/lopinavir/ritonavir) did not achieve the protocol-defined virological threshold of efficacy.},
  keywords = {{CAMEROUN} ; {SENEGAL}},
  booktitle = {},
  journal = {{A}ntiviral {T}herapy},
  volume = {19},
  numero = {1},
  pages = {51--59},
  ISSN = {1359-6535},
  year = {2014},
  DOI = {10.3851/imp2675},
  URL = {https://www.documentation.ird.fr/hor/fdi:010062019},
}